SI2024499T1 - Analogues of the oligonucleotide, with cationic links between subunits - Google Patents
Analogues of the oligonucleotide, with cationic links between subunits Download PDFInfo
- Publication number
- SI2024499T1 SI2024499T1 SI200732002T SI200732002T SI2024499T1 SI 2024499 T1 SI2024499 T1 SI 2024499T1 SI 200732002 T SI200732002 T SI 200732002T SI 200732002 T SI200732002 T SI 200732002T SI 2024499 T1 SI2024499 T1 SI 2024499T1
- Authority
- SI
- Slovenia
- Prior art keywords
- oligomer
- connections
- cationic
- subunits
- carbon atoms
- Prior art date
Links
- 125000002091 cationic group Chemical group 0.000 title claims abstract 17
- 108091034117 Oligonucleotide Proteins 0.000 title claims abstract 3
- 150000001413 amino acids Chemical class 0.000 claims abstract 6
- 230000000692 anti-sense effect Effects 0.000 claims abstract 3
- 230000007935 neutral effect Effects 0.000 claims abstract 3
- 239000004475 Arginine Substances 0.000 claims abstract 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims abstract 2
- 150000001484 arginines Chemical class 0.000 claims abstract 2
- 230000000694 effects Effects 0.000 claims abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 10
- 125000004432 carbon atom Chemical group C* 0.000 claims 9
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 235000001014 amino acid Nutrition 0.000 claims 5
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 125000003282 alkyl amino group Chemical group 0.000 claims 3
- 125000004429 atom Chemical group 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 2
- -1 R4 is H Chemical group 0.000 claims 2
- 150000001371 alpha-amino acids Chemical class 0.000 claims 2
- 235000008206 alpha-amino acids Nutrition 0.000 claims 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 claims 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 229910052698 phosphorus Inorganic materials 0.000 claims 2
- 239000011574 phosphorus Substances 0.000 claims 2
- 125000004193 piperazinyl group Chemical group 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 239000004215 Carbon black (E152) Substances 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 1
- 229960002684 aminocaproic acid Drugs 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 229940000635 beta-alanine Drugs 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 229930195733 hydrocarbon Natural products 0.000 claims 1
- 150000002430 hydrocarbons Chemical class 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 108010078791 Carrier Proteins Proteins 0.000 abstract 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 abstract 1
- 108010082406 peptide permease Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
- C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/314—Phosphoramidates
- C12N2310/3145—Phosphoramidates with the nitrogen in 3' or 5'-position
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3233—Morpholino-type ring
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3513—Protein; Peptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/50—Methods for regulating/modulating their activity
- C12N2320/51—Methods for regulating/modulating their activity modulating the chemical stability, e.g. nuclease-resistance
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/30—Production chemically synthesised
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Virology (AREA)
- AIDS & HIV (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (20)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/432,155 US20070037763A1 (en) | 2003-12-24 | 2006-05-10 | Oligonucleotide compound and method for treating nidovirus infections |
| US11/431,968 US8785407B2 (en) | 2006-05-10 | 2006-05-10 | Antisense antiviral agent and method for treating ssRNA viral infection |
| US11/432,031 US8084433B2 (en) | 2004-09-16 | 2006-05-10 | Antisense antiviral compound and method for treating ssRNA viral infection |
| US11/432,216 US7625873B2 (en) | 2004-07-02 | 2006-05-10 | Antisense antibacterial method and compound |
| US80014506P | 2006-05-11 | 2006-05-11 | |
| US79997606P | 2006-05-11 | 2006-05-11 | |
| US80007606P | 2006-05-11 | 2006-05-11 | |
| US80012006P | 2006-05-11 | 2006-05-11 | |
| US11/433,724 US7888012B2 (en) | 2005-02-09 | 2006-05-11 | Antisense composition and method for treating muscle atrophy |
| US11/433,033 US8415313B2 (en) | 2004-01-23 | 2006-05-11 | Antisense oligomers and methods for inducing immune tolerance and immunosuppression |
| US11/433,214 US8067569B2 (en) | 2000-05-04 | 2006-05-11 | Splice-region antisense composition and method |
| US11/433,840 US7507196B2 (en) | 2004-11-01 | 2006-05-11 | Antisense antiviral compounds and methods for treating a filovirus infection |
| US11/433,257 US20070037764A1 (en) | 2003-10-23 | 2006-05-11 | Method and antisense composition for selective inhibition of HIV infection in hematopoietic cells |
| US11/433,213 US20070004661A1 (en) | 2004-10-26 | 2006-05-11 | Antisense antiviral compound and method for treating influenza viral infection |
| US11/518,058 US8329668B2 (en) | 2005-09-08 | 2006-09-08 | Antisense antiviral compound and method for treating picornavirus infection |
| US11/517,757 US8524676B2 (en) | 2005-09-08 | 2006-09-08 | Method for treating enterovirus or rhinovirus infection using antisense antiviral compounds |
| US11/595,161 US20070111962A1 (en) | 2005-11-08 | 2006-11-08 | Immunosuppression compound and treatment method |
| US11/715,572 US7582615B2 (en) | 2006-03-07 | 2007-03-07 | Antisense antiviral compound and method for treating arenavirus infection |
| EP07861308.0A EP2024499B1 (en) | 2006-05-10 | 2007-05-10 | Oligonucleotide analogs having cationic intersubunit linkages |
| PCT/US2007/011435 WO2008036127A2 (en) | 2006-05-10 | 2007-05-10 | Oligonucleotide analogs having cationic intersubunit linkages |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI2024499T1 true SI2024499T1 (en) | 2018-04-30 |
Family
ID=40134113
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI200732002T SI2024499T1 (en) | 2006-05-10 | 2007-05-10 | Analogues of the oligonucleotide, with cationic links between subunits |
| SI200731980T SI2735568T1 (en) | 2006-05-10 | 2007-05-10 | Analogues of the oligonucleotide, with cationic links between subunits |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI200731980T SI2735568T1 (en) | 2006-05-10 | 2007-05-10 | Analogues of the oligonucleotide, with cationic links between subunits |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US7943762B2 (enExample) |
| EP (2) | EP2024499B1 (enExample) |
| JP (1) | JP2010505741A (enExample) |
| AU (1) | AU2007297861A1 (enExample) |
| CA (1) | CA2651881A1 (enExample) |
| CY (2) | CY1120409T1 (enExample) |
| DK (2) | DK2735568T3 (enExample) |
| ES (2) | ES2657400T3 (enExample) |
| HU (2) | HUE036995T2 (enExample) |
| LT (2) | LT2024499T (enExample) |
| PL (1) | PL2735568T3 (enExample) |
| PT (1) | PT2735568T (enExample) |
| SI (2) | SI2024499T1 (enExample) |
| WO (1) | WO2008036127A2 (enExample) |
Families Citing this family (123)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20020097241A (ko) | 2000-05-04 | 2002-12-31 | 에이브이아이 바이오파마 인코포레이티드 | 스플라이스-영역 안티센스 조성물 및 방법 |
| US7468418B2 (en) | 2003-04-29 | 2008-12-23 | Avi Biopharma., Inc. | Compositions for enhancing transport of molecules into cells |
| US20050222068A1 (en) * | 2003-10-23 | 2005-10-06 | Mourich Dan V | Method and antisense composition for selective inhibition of HIV infection in hematopoietic cells |
| US20050171044A1 (en) * | 2003-12-24 | 2005-08-04 | Stein David A. | Oligonucleotide compound and method for treating nidovirus infections |
| EP1713332A4 (en) * | 2004-01-23 | 2010-08-18 | Avi Biopharma Inc | ANTISENSE OLIGOMERS AND METHOD FOR INDUCTION OF IMMUNOTHERAPY AND IMMUNOSUPPRESSION |
| US20050288246A1 (en) | 2004-05-24 | 2005-12-29 | Iversen Patrick L | Peptide conjugated, inosine-substituted antisense oligomer compound and method |
| EP1766010B1 (en) | 2004-06-28 | 2011-02-16 | The University Of Western Australia | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
| AU2005327188C8 (en) | 2004-07-02 | 2011-09-22 | Avi Biopharma, Inc. | Antisense antibacterial method and compound |
| US8129352B2 (en) * | 2004-09-16 | 2012-03-06 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating ssRNA viral infection |
| US7524829B2 (en) * | 2004-11-01 | 2009-04-28 | Avi Biopharma, Inc. | Antisense antiviral compounds and methods for treating a filovirus infection |
| EP1855694B1 (en) * | 2005-02-09 | 2020-12-02 | Sarepta Therapeutics, Inc. | Antisense composition for treating muscle atrophy |
| US8067571B2 (en) | 2005-07-13 | 2011-11-29 | Avi Biopharma, Inc. | Antibacterial antisense oligonucleotide and method |
| US8524676B2 (en) * | 2005-09-08 | 2013-09-03 | Sarepta Therapeutics, Inc. | Method for treating enterovirus or rhinovirus infection using antisense antiviral compounds |
| US8501704B2 (en) | 2005-11-08 | 2013-08-06 | Sarepta Therapeutics, Inc. | Immunosuppression compound and treatment method |
| US8785407B2 (en) * | 2006-05-10 | 2014-07-22 | Sarepta Therapeutics, Inc. | Antisense antiviral agent and method for treating ssRNA viral infection |
| US20070265215A1 (en) * | 2006-05-11 | 2007-11-15 | Iversen Patrick L | Antisense restenosis composition and method |
| ES2694726T3 (es) * | 2007-06-29 | 2018-12-26 | Sarepta Therapeutics, Inc. | Conjugados peptídicos específicos de tejido y métodos |
| AU2015200600B2 (en) * | 2007-06-29 | 2017-04-20 | Sarepta Therapeutics, Inc. | Tissue specific peptide conjugates and methods |
| US20100016215A1 (en) | 2007-06-29 | 2010-01-21 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
| WO2009014177A1 (ja) * | 2007-07-25 | 2009-01-29 | Ajinomoto Co., Inc. | ジベンゾフルベン誘導体の淘汰方法 |
| HRP20140646T1 (hr) * | 2007-11-15 | 2014-09-26 | Sarepta Therapeutics, Inc. | Postupak sinteze morfolino oligomera |
| US8299206B2 (en) * | 2007-11-15 | 2012-10-30 | Avi Biopharma, Inc. | Method of synthesis of morpholino oligomers |
| US8076476B2 (en) * | 2007-11-15 | 2011-12-13 | Avi Biopharma, Inc. | Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits |
| CA2710013A1 (en) * | 2007-12-28 | 2009-07-09 | Avi Biopharma, Inc. | Immunomodulatory agents and methods of use |
| DK3133160T3 (en) | 2008-10-24 | 2019-04-01 | Sarepta Therapeutics Inc | EXON SKIP COMPOSITIONS FOR DMD |
| WO2010080554A1 (en) * | 2008-12-17 | 2010-07-15 | Avi Biopharma, Inc. | Antisense compositions and methods for modulating contact hypersensitivity or contact dermatitis |
| JP5875976B2 (ja) | 2009-06-01 | 2016-03-02 | ヘイロー−バイオ アールエヌエーアイ セラピューティクス， インコーポレイテッド | 多価ｒｎａ干渉のためのポリヌクレオチド、組成物およびそれらの使用方法 |
| US20110269665A1 (en) | 2009-06-26 | 2011-11-03 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
| US9914745B2 (en) | 2009-08-14 | 2018-03-13 | Indian Association For The Cultivation Of Science | Morpholino-based antisense agent |
| US8999675B2 (en) * | 2009-08-31 | 2015-04-07 | Gen-Probe Incorporated | Dengue virus assay |
| BR112012011195B1 (pt) | 2009-11-12 | 2024-02-15 | The University Of Western Australia | Oligonucleotídeo antissentido, composição farmacêutica e uso de uma composição farmacêutica |
| KR101944119B1 (ko) | 2009-11-13 | 2019-01-30 | 사렙타 쎄러퓨틱스 인코퍼레이티드 | 안티센스 항바이러스 화합물 및 인플루엔자 바이러스 감염을 치료하는 방법 |
| EP2542678B1 (en) | 2010-03-04 | 2017-04-12 | InteRNA Technologies B.V. | A MiRNA MOLECULE DEFINED BY ITS SOURCE AND ITS THERAPEUTIC USES IN CANCER ASSOCIATED WITH EMT |
| US9068185B2 (en) | 2010-03-12 | 2015-06-30 | Sarepta Therapeutics, Inc. | Antisense modulation of nuclear hormone receptors |
| EP2569431B1 (en) * | 2010-05-13 | 2015-09-23 | Sarepta Therapeutics, Inc. | Methods for identifying compounds which modulate interleukins 17 and 23 signaling activity |
| KR101981705B1 (ko) * | 2010-05-28 | 2019-05-24 | 사렙타 쎄러퓨틱스, 인코퍼레이티드 | 변형된 서브유니트간 결합 및/또는 말단 그룹을 갖는 올리고뉴클레오타이드 유사체 |
| AU2013202731B2 (en) * | 2010-05-28 | 2016-04-21 | Sarepta Therapeutics, Inc. | Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups |
| AU2011274619B2 (en) | 2010-07-06 | 2016-11-10 | Interna Technologies Bv | miRNA and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated BRAF pathway |
| US8198429B2 (en) | 2010-08-09 | 2012-06-12 | Avi Biopharma, Inc. | Antisense antiviral compounds and methods for treating a filovirus infection |
| TWI541024B (zh) | 2010-09-01 | 2016-07-11 | 日本新藥股份有限公司 | 反義核酸 |
| WO2012031243A2 (en) | 2010-09-03 | 2012-03-08 | Avi Biopharma, Inc. | dsRNA MOLECULES COMPRISING OLIGONUCLEOTIDE ANALOGS HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS |
| PT2623507T (pt) * | 2010-09-30 | 2016-12-23 | Nippon Shinyaku Co Ltd | Derivado de ácido morfolino-nucleico |
| EP2474617A1 (en) | 2011-01-11 | 2012-07-11 | InteRNA Technologies BV | Mir for treating neo-angiogenesis |
| WO2012100156A1 (en) | 2011-01-20 | 2012-07-26 | Hercules Incorporated | Enhanced dry strength and drainage performance by combining glyoxalated acrylamide-containing polymers with cationic aqueous dispersion polymers |
| KR102183273B1 (ko) | 2011-05-05 | 2020-11-27 | 사렙타 쎄러퓨틱스, 인코퍼레이티드 | 펩타이드 올리고뉴클레오타이드 접합체 |
| US9161948B2 (en) | 2011-05-05 | 2015-10-20 | Sarepta Therapeutics, Inc. | Peptide oligonucleotide conjugates |
| AU2012284259A1 (en) | 2011-07-15 | 2014-03-06 | Sarepta Therapeutics, Inc. | Methods and compositions for manipulating translation of protein isoforms from alternative initiation start sites |
| US20130085139A1 (en) | 2011-10-04 | 2013-04-04 | Royal Holloway And Bedford New College | Oligomers |
| CA2854907C (en) * | 2011-11-18 | 2020-03-10 | Sarepta Therapeutics, Inc. | Functionally-modified oligonucleotides and subunits thereof |
| AU2012345638C1 (en) * | 2011-11-30 | 2018-10-18 | Sarepta Therapeutics, Inc. | Induced exon inclusion in spinal muscle atrophy |
| EP3858847A1 (en) | 2011-11-30 | 2021-08-04 | Sarepta Therapeutics, Inc. | Oligonucleotides for treating expanded repeat diseases |
| HRP20181022T1 (hr) | 2011-12-08 | 2018-08-24 | Sarepta Therapeutics, Inc. | Analozi oligonukleotida koji ciljaju ljudski lmna |
| EP3369818B1 (en) | 2011-12-22 | 2021-06-09 | InteRNA Technologies B.V. | Mirna for treating head and neck cancer |
| NZ700399A (en) | 2012-03-20 | 2016-07-29 | Sarepta Therapeutics Inc | Boronic acid conjugates of oligonucleotide analogues |
| KR102240217B1 (ko) | 2012-09-25 | 2021-04-14 | 젠자임 코포레이션 | 근긴장성 이영양증의 치료용 펩티드-결합 모르폴리노 안티센스 올리고뉴클레오티드 |
| EP2917348A1 (en) | 2012-11-06 | 2015-09-16 | InteRNA Technologies B.V. | Combination for use in treating diseases or conditions associated with melanoma, or treating diseases or conditions associated with activated b-raf pathway |
| EP3885439A1 (en) | 2012-12-20 | 2021-09-29 | Sarepta Therapeutics, Inc. | Improved exon skipping compositions for treating muscular dystrophy |
| CN103060325B (zh) * | 2013-01-14 | 2015-01-07 | 韩健宝 | 抗猪流行性腹泻病毒pedv的反义核酸及肽核酸pna |
| EP3633035A1 (en) | 2013-03-14 | 2020-04-08 | Sarepta Therapeutics, Inc. | Exon skipping compositions for treating muscular dystrophy |
| KR20220061280A (ko) | 2013-03-14 | 2022-05-12 | 사렙타 쎄러퓨틱스 인코퍼레이티드 | 근육 이영양증의 치료를 위한 엑손 스키핑 조성물 |
| BR112015022998A2 (pt) | 2013-03-15 | 2017-11-14 | Sarepta Therapeutics Inc | composições melhoradas para o tratamento de distrofia muscular |
| IL282239B2 (en) | 2013-09-05 | 2023-10-01 | Sarepta Therapeutics Inc | Antisense-induced exon2 inclusion in acid alpha-glucosidase |
| ES2739850T3 (es) | 2013-09-11 | 2020-02-04 | Synthena Ag | Acidos nucleicos y procedimientos para el tratamiento de la enfermedad de Pompe |
| EP3146050B1 (en) | 2014-05-23 | 2020-08-12 | Genzyme Corporation | Inhibiting or downregulating glycogen synthase by creating premature stop codons using antisense oligonucleotides |
| CN106795186B (zh) | 2014-10-14 | 2021-03-02 | 味之素株式会社 | 吗啉代寡核苷酸的制备方法 |
| MA41795A (fr) | 2015-03-18 | 2018-01-23 | Sarepta Therapeutics Inc | Exclusion d'un exon induite par des composés antisens dans la myostatine |
| EP3302497A4 (en) | 2015-06-01 | 2019-01-16 | Sarepta Therapeutics, Inc. | ANTISENSE INDUSTRY EXONEXCLUSION IN TYPE VII COLLAGEN |
| WO2016196897A1 (en) | 2015-06-04 | 2016-12-08 | Sarepta Therapeutics, Inc. | Methods and compounds for treatment of lymphocyte-related diseases and conditions |
| AU2016312530A1 (en) | 2015-08-24 | 2018-03-01 | Halo-Bio Rnai Therapeutics, Inc. | Polynucleotide nanoparticles for the modulation of gene expression and uses thereof |
| US10905709B2 (en) | 2015-08-28 | 2021-02-02 | Sarepta Therapeutics, Inc. | Modified antisense oligomers for exon inclusion in spinal muscular atrophy |
| EA201890811A1 (ru) | 2015-09-30 | 2018-09-28 | Сарепта Терапьютикс, Инк. | Способы лечения мышечной дистрофии |
| EA201890908A1 (ru) | 2015-10-09 | 2018-10-31 | Сарепта Терапьютикс, Инк. | Композиции и способы для лечения мышечной дистрофии дюшенна и сходных нарушений |
| MA45328A (fr) | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | Compositions acide nucléique-polypeptide et utilisations de celles-ci |
| KR102522059B1 (ko) | 2016-04-18 | 2023-04-14 | 사렙타 쎄러퓨틱스 인코퍼레이티드 | 안티센스 올리고머, 및 산성 알파-글루코시다제 유전자와 연관된 질환을 치료하기 위한 이의 사용 방법 |
| EA201892467A1 (ru) | 2016-04-29 | 2019-05-31 | Сарепта Терапьютикс, Инк. | Олигонуклеотидные аналоги, нацеленные на lmna человека |
| MA49775A (fr) * | 2016-05-24 | 2020-06-10 | Sarepta Therapeutics Inc | Procédés de préparation d'oligomères morpholino de phosphorodiamidate |
| JP2019534862A (ja) | 2016-09-20 | 2019-12-05 | ザ リージェンツ オブ ザ ユニヴァーシティ オブ コロラド，ア ボディ コーポレイト | ホスホルアミダイト化学を使用する骨格修飾モルホリノオリゴヌクレオチド及びキメラの合成 |
| KR102552428B1 (ko) | 2016-12-19 | 2023-07-06 | 사렙타 쎄러퓨틱스 인코퍼레이티드 | 근육 이상증에 대한 엑손 스킵핑 올리고머 결합체 |
| KR20190104381A (ko) | 2017-01-06 | 2019-09-09 | 어비디티 바이오사이언시스 엘엘씨 | 핵산-폴리펩티드 조성물 및 엑손 스키핑을 유도하는 방법 |
| US11693013B2 (en) | 2017-03-10 | 2023-07-04 | UCL Business Ltd. | Method relating to myostatin pathway inhibition |
| SG10201705285SA (en) * | 2017-06-27 | 2019-01-30 | Agency Science Tech & Res | Antisense oligonucleotides |
| GB201711809D0 (en) | 2017-07-21 | 2017-09-06 | Governors Of The Univ Of Alberta | Antisense oligonucleotide |
| JP7218361B2 (ja) * | 2017-09-25 | 2023-02-06 | サレプタ セラピューティクス， インコーポレイテッド | 高速流動合成を介してホスホロジアミデートモルホリノオリゴマーを調製するための方法 |
| CN111655268B (zh) | 2017-10-04 | 2024-03-26 | 艾维迪提生物科学公司 | 核酸-多肽组合物及其用途 |
| WO2019079386A1 (en) * | 2017-10-17 | 2019-04-25 | Sarepta Therapeutics, Inc. | CELL PENETRATION PEPTIDES FOR ANTISENSE ADMINISTRATION |
| JP7356416B2 (ja) * | 2017-10-17 | 2023-10-04 | サレプタ セラピューティクス， インコーポレイテッド | 二環式ペプチドオリゴヌクレオチドコンジュゲート |
| JP7394753B2 (ja) | 2017-10-18 | 2023-12-08 | サレプタ セラピューティクス， インコーポレイテッド | アンチセンスオリゴマー化合物 |
| AU2018358016A1 (en) | 2017-11-03 | 2020-05-07 | Interna Technologies B.V. | MiRNA molecule, equivalent, antagomir, or source thereof for treating and/or diagnosing a condition and/or a disease associated with neuronal deficiency or for neuronal (re)generation |
| CN118638788A (zh) | 2017-12-06 | 2024-09-13 | 艾维迪提生物科学公司 | 治疗肌萎缩和强直性肌营养不良的组合物和方法 |
| AU2019218557A1 (en) | 2018-02-12 | 2020-08-20 | Interna Technologies B.V. | Anticancer microRNA and lipid formulations thereof |
| TW202002990A (zh) * | 2018-03-16 | 2020-01-16 | 美商薩羅塔治療公司 | 用於反義遞送之嵌合肽 |
| WO2019216433A1 (ja) * | 2018-05-10 | 2019-11-14 | 日本新薬株式会社 | オリゴ核酸化合物の製造方法 |
| IL319265A (en) | 2018-12-21 | 2025-04-01 | Avidity Biosciences Inc | Anti-transferrin receptor antibodies and their uses |
| GB201821269D0 (en) | 2018-12-28 | 2019-02-13 | Nippon Shinyaku Co Ltd | Myostatin signal inhibitor |
| US20220098578A1 (en) | 2019-01-31 | 2022-03-31 | Bar Ilan University | Neoantigens created by aberrant-induced splicing and uses thereof in enhancing immunotherapy |
| AU2020287880A1 (en) | 2019-06-06 | 2022-01-20 | Avidity Biosciences, Inc. | UNA amidites and uses thereof |
| AU2020289464B2 (en) | 2019-06-06 | 2025-12-04 | Avidity Biosciences, Inc. | Nucleic acid-polypeptide compositions and uses thereof |
| WO2020257489A1 (en) | 2019-06-19 | 2020-12-24 | Sarepta Therapeutics, Inc. | Methods for treating muscular dystrophy |
| TWI874546B (zh) | 2019-12-26 | 2025-03-01 | 日商日本新藥股份有限公司 | 誘導外顯子５０的跳讀的反義核酸 |
| CA3173049A1 (en) | 2020-02-28 | 2021-09-02 | Nippon Shinyaku Co., Ltd. | Antisense nucleic acid inducing skipping of exon 51 |
| MX2022011499A (es) | 2020-03-19 | 2022-10-07 | Avidity Biosciences Inc | Composiciones y metodos para tratar la distrofia muscular facioescapulohumeral. |
| EP4656242A2 (en) | 2020-03-27 | 2025-12-03 | Avidity Biosciences, Inc. | Compositions and methods of treating muscle dystrophy |
| EP4150092A4 (en) | 2020-05-11 | 2024-11-06 | Stoke Therapeutics, Inc. | OPA1 ANTISENSE OLIGOMERS FOR THE TREATMENT OF DISEASES AND CONDITIONS |
| CN111575409B (zh) * | 2020-05-23 | 2023-04-18 | 黑龙江八一农垦大学 | 基于整合素配体识别肽抑制猪流行性腹泻病毒感染的研究方法 |
| CA3202708A1 (en) | 2020-11-23 | 2022-05-27 | Alpha Anomeric Sas | Nucleic acid duplexes |
| US12378267B2 (en) | 2021-06-17 | 2025-08-05 | Entrada Therapeutics, Inc. | Synthesis of FMOC-protected morpholino monomers and oligomers |
| IL309626A (en) | 2021-06-23 | 2024-02-01 | Nippon Shinyaku Co Ltd | A combination of antisense oligomers |
| EP4368176A4 (en) | 2021-07-08 | 2025-06-25 | Nippon Shinyaku Co., Ltd. | Nephrotoxicity reducing agent |
| WO2023282346A1 (ja) | 2021-07-08 | 2023-01-12 | 日本新薬株式会社 | 析出抑制剤 |
| CN118475355A (zh) | 2021-07-08 | 2024-08-09 | 日本新药株式会社 | 肾毒性减轻剂 |
| US20250011777A1 (en) | 2021-09-03 | 2025-01-09 | Sarepta Therapeutics, Inc. | Delivery of anitsense oligomers by mirror image peptides |
| CA3231330A1 (en) | 2021-09-16 | 2023-03-23 | Avidity Biosciences, Inc. | Compositions and methods of treating facioscapulohumeral muscular dystrophy |
| MX2024003690A (es) | 2021-09-30 | 2024-06-19 | Sarepta Therapeutics Inc | Oligonucleótidos antisentido que tienen una o más unidades abásicas. |
| JP2024539223A (ja) | 2021-10-22 | 2024-10-28 | サレプタ セラピューティクス， インコーポレイテッド | 末梢ミエリンタンパク質２２関連疾患の処置のためのモルフォリノオリゴマー |
| US12071621B2 (en) | 2022-04-05 | 2024-08-27 | Avidity Biosciences, Inc. | Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping |
| WO2023205451A1 (en) | 2022-04-22 | 2023-10-26 | Entrada Therapeutics, Inc. | Cyclic peptides for delivering therapeutics |
| EP4590311A2 (en) | 2022-09-21 | 2025-07-30 | Sarepta Therapeutics, Inc. | Dmd antisense oligonucleotide-mediated exon skipping efficiency |
| IT202200026595A1 (it) | 2022-12-22 | 2024-06-22 | Fond Telethon Ets | Nuovi inibitori di regolatori epigenetici |
| TW202444908A (zh) | 2023-04-06 | 2024-11-16 | 大陸商上海舶望製藥有限公司 | ５＇－膦酸酯修飾的核苷類似物及其製備的寡核苷酸 |
| TW202442246A (zh) | 2023-04-27 | 2024-11-01 | 美商薩羅塔治療公司 | 用於治療慢性腎病之反義寡聚物 |
| US20250171776A1 (en) | 2023-08-02 | 2025-05-29 | Sarepta Therapeutics, Inc. | Non-canonical cell-penetrating peptides for antisense oligomer delivery |
| WO2025085810A2 (en) | 2023-10-18 | 2025-04-24 | Sarepta Therapeutics, Inc. | Antisense oligomers for treatment of centronuclear myopathies |
| CN120058705A (zh) * | 2025-04-29 | 2025-05-30 | 苏州诺维康生物科技有限公司 | 一种医药中间体PMO-G(N2-iBu)的合成方法 |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5185444A (en) | 1985-03-15 | 1993-02-09 | Anti-Gene Deveopment Group | Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages |
| US5506337A (en) * | 1985-03-15 | 1996-04-09 | Antivirals Inc. | Morpholino-subunit combinatorial library and method |
| US5166315A (en) | 1989-12-20 | 1992-11-24 | Anti-Gene Development Group | Sequence-specific binding polymers for duplex nucleic acids |
| EP0215942B1 (en) * | 1985-03-15 | 1995-07-12 | Antivirals Inc. | Polynucleotide assay reagent and method |
| US5521063A (en) | 1985-03-15 | 1996-05-28 | Antivirals Inc. | Polynucleotide reagent containing chiral subunits and methods of use |
| US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| US5217866A (en) | 1985-03-15 | 1993-06-08 | Anti-Gene Development Group | Polynucleotide assay reagent and method |
| AU655164B2 (en) * | 1989-12-20 | 1994-12-08 | Antivirals Inc. | Uncharged morpholino-based polymers having phosphorous-containing chiral intersubunit linkages |
| US5852188A (en) * | 1990-01-11 | 1998-12-22 | Isis Pharmaceuticals, Inc. | Oligonucleotides having chiral phosphorus linkages |
| US5580767A (en) * | 1990-08-14 | 1996-12-03 | Isis Pharmaceuticals, Inc. | Inhibition of influenza viruses by antisense oligonucleotides |
| AU659482B2 (en) | 1991-06-28 | 1995-05-18 | Massachusetts Institute Of Technology | Localized oligonucleotide therapy |
| US5576302A (en) * | 1991-10-15 | 1996-11-19 | Isis Pharmaceuticals, Inc. | Oligonucleotides for modulating hepatitis C virus having phosphorothioate linkages of high chiral purity |
| CA2125269A1 (en) * | 1991-12-23 | 1993-07-08 | Chiron Diagnostics Corporation | Hav probes for use in solution phase sandwich hybridization assays |
| US6174868B1 (en) * | 1992-09-10 | 2001-01-16 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of hepatitis C virus-associated diseases |
| US5801154A (en) * | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
| US6060456A (en) * | 1993-11-16 | 2000-05-09 | Genta Incorporated | Chimeric oligonucleoside compounds |
| US5734039A (en) * | 1994-09-15 | 1998-03-31 | Thomas Jefferson University | Antisense oligonucleotides targeting cooperating oncogenes |
| GB9510718D0 (en) | 1995-05-26 | 1995-07-19 | Sod Conseils Rech Applic | Antisense oligonucleotides |
| US5955318A (en) * | 1995-08-14 | 1999-09-21 | Abbott Laboratories | Reagents and methods useful for controlling the translation of hepatitis GBV proteins |
| US6686338B1 (en) | 1996-02-23 | 2004-02-03 | The Board Of Regents Of The University Of Nebraska | Enzyme inhibitors for metabolic redirection |
| US6245747B1 (en) | 1996-03-12 | 2001-06-12 | The Board Of Regents Of The University Of Nebraska | Targeted site specific antisense oligodeoxynucleotide delivery method |
| BR9809138A (pt) * | 1997-05-21 | 2001-08-28 | Trustees For The Leland Stanfo | Conjugado e método para aumentar o transporte de um composto selecionado atravessando uma membrana biológica |
| AUPP398498A0 (en) | 1998-06-09 | 1998-07-02 | Silverbrook Research Pty Ltd | A method of manufacture of an image creation apparatus (ijm44) |
| US6133246A (en) * | 1997-08-13 | 2000-10-17 | Isis Pharmaceuticals Inc. | Antisense oligonucleotide compositions and methods for the modulation of JNK proteins |
| US6228579B1 (en) * | 1997-11-14 | 2001-05-08 | San Diego State University Foundation | Method for identifying microbial proliferation genes |
| WO2000002588A1 (en) | 1998-07-13 | 2000-01-20 | The Board Of Regents Of The University Of Nebraska | Targeted site specific drug delivery compositions and method of use |
| CA2360997A1 (en) * | 1999-01-29 | 2000-08-03 | Avi Biopharma, Inc. | Non-invasive method for detecting target rna |
| US7094765B1 (en) | 1999-01-29 | 2006-08-22 | Avi Biopharma, Inc. | Antisense restenosis composition and method |
| US20030095953A1 (en) | 1999-11-12 | 2003-05-22 | Myles C. Cabot | Methods of reversing drug resistance in cancer cells |
| DE60038695T2 (de) * | 1999-11-29 | 2009-05-28 | Avi Biopharma, Inc., Corvallis | Gegen bakterielle 16s und 23s rrnas gerichtete ungeladene antisense oligonukleotide und deren verwendungen |
| CA2396068A1 (en) * | 2000-01-04 | 2001-07-12 | Avi Biopharma, Inc. | Antisense antibacterial cell division composition and method |
| KR20020097241A (ko) * | 2000-05-04 | 2002-12-31 | 에이브이아이 바이오파마 인코포레이티드 | 스플라이스-영역 안티센스 조성물 및 방법 |
| JP2004523465A (ja) | 2000-05-17 | 2004-08-05 | エイブイアイ バイオファーマ， インコーポレイテッド | 薬物の薬物動態を改善するためのアンチセンス酵素インヒビター |
| US6841542B2 (en) | 2000-07-06 | 2005-01-11 | Avi Biopharma, Inc. | Transforming growth factor beta (TGF-β) blocking agent-treated stem cell composition and method |
| KR20040004629A (ko) * | 2001-05-17 | 2004-01-13 | 에이브이아이 바이오파마 인코포레이티드 | ｃ-ｍｙｃ 안티센스 올리고머를 사용한 암치료를 위한조합 접근법 |
| US20030224353A1 (en) | 2001-10-16 | 2003-12-04 | Stein David A. | Antisense antiviral agent and method for treating ssRNA viral infection |
| CN100547071C (zh) * | 2001-10-16 | 2009-10-07 | Avi生物制药公司 | 用于治疗单链rna病毒感染的抗病毒反义核酸的试剂和方法 |
| US20030207907A1 (en) | 2002-05-03 | 2003-11-06 | Iversen Patrick L. | Delivery of microparticle-conjugated drugs for inhibition of stenosis |
| NZ538719A (en) * | 2002-09-13 | 2008-05-30 | Replicor Inc | Non-sequence complementary antiviral oligonucleotides |
| EP2366803B8 (en) * | 2002-10-16 | 2015-08-19 | Gen-Probe Incorporated | Compositions and methods for detecting west nile virus |
| JP4791043B2 (ja) | 2002-12-31 | 2011-10-12 | プロリゴ・エルエルシー | 同一固体支持体上で、２以上のオリゴヌクレオチドをタンデムに合成するための方法および組成物 |
| DE602004030583D1 (de) | 2003-08-05 | 2011-01-27 | Avi Biopharma Inc | Oligonukleotidanalog und verfahren zur behandlung von flavivirusinfektionen |
| US20050171044A1 (en) | 2003-12-24 | 2005-08-04 | Stein David A. | Oligonucleotide compound and method for treating nidovirus infections |
| EP1713332A4 (en) * | 2004-01-23 | 2010-08-18 | Avi Biopharma Inc | ANTISENSE OLIGOMERS AND METHOD FOR INDUCTION OF IMMUNOTHERAPY AND IMMUNOSUPPRESSION |
| US20050288246A1 (en) * | 2004-05-24 | 2005-12-29 | Iversen Patrick L | Peptide conjugated, inosine-substituted antisense oligomer compound and method |
| AU2005327188C8 (en) * | 2004-07-02 | 2011-09-22 | Avi Biopharma, Inc. | Antisense antibacterial method and compound |
| US8129352B2 (en) * | 2004-09-16 | 2012-03-06 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating ssRNA viral infection |
| US8357664B2 (en) * | 2004-10-26 | 2013-01-22 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating influenza viral infection |
| US7524829B2 (en) * | 2004-11-01 | 2009-04-28 | Avi Biopharma, Inc. | Antisense antiviral compounds and methods for treating a filovirus infection |
| TW200622777A (en) * | 2004-12-31 | 2006-07-01 | Inventec Corp | Manufacturing-order giving system and method thereof |
| CA2621964A1 (en) | 2005-09-08 | 2007-03-15 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating picornavirus infection |
| US8524676B2 (en) | 2005-09-08 | 2013-09-03 | Sarepta Therapeutics, Inc. | Method for treating enterovirus or rhinovirus infection using antisense antiviral compounds |
| US8785407B2 (en) * | 2006-05-10 | 2014-07-22 | Sarepta Therapeutics, Inc. | Antisense antiviral agent and method for treating ssRNA viral infection |
-
2007
- 2007-05-10 JP JP2009509880A patent/JP2010505741A/ja active Pending
- 2007-05-10 PT PT131869737T patent/PT2735568T/pt unknown
- 2007-05-10 CA CA002651881A patent/CA2651881A1/en not_active Abandoned
- 2007-05-10 SI SI200732002T patent/SI2024499T1/en unknown
- 2007-05-10 PL PL13186973T patent/PL2735568T3/pl unknown
- 2007-05-10 WO PCT/US2007/011435 patent/WO2008036127A2/en not_active Ceased
- 2007-05-10 HU HUE13186973A patent/HUE036995T2/hu unknown
- 2007-05-10 HU HUE07861308A patent/HUE035799T2/en unknown
- 2007-05-10 ES ES07861308.0T patent/ES2657400T3/es active Active
- 2007-05-10 EP EP07861308.0A patent/EP2024499B1/en active Active
- 2007-05-10 DK DK13186973.7T patent/DK2735568T3/da active
- 2007-05-10 LT LTEP07861308.0T patent/LT2024499T/lt unknown
- 2007-05-10 DK DK07861308.0T patent/DK2024499T3/da active
- 2007-05-10 EP EP13186973.7A patent/EP2735568B8/en active Active
- 2007-05-10 US US11/801,885 patent/US7943762B2/en active Active
- 2007-05-10 AU AU2007297861A patent/AU2007297861A1/en not_active Abandoned
- 2007-05-10 ES ES13186973.7T patent/ES2645410T3/es active Active
- 2007-05-10 SI SI200731980T patent/SI2735568T1/en unknown
- 2007-05-10 LT LTEP13186973.7T patent/LT2735568T/lt unknown
-
2017
- 2017-11-01 CY CY20171101137T patent/CY1120409T1/el unknown
-
2018
- 2018-01-25 CY CY20181100102T patent/CY1120486T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HUE036995T2 (hu) | 2018-08-28 |
| EP2735568B8 (en) | 2017-09-27 |
| WO2008036127A2 (en) | 2008-03-27 |
| EP2735568B1 (en) | 2017-08-02 |
| US7943762B2 (en) | 2011-05-17 |
| ES2657400T3 (es) | 2018-03-05 |
| LT2735568T (lt) | 2017-11-27 |
| ES2645410T3 (es) | 2017-12-05 |
| EP2024499B1 (en) | 2017-10-25 |
| JP2010505741A (ja) | 2010-02-25 |
| SI2735568T1 (en) | 2018-01-31 |
| US20090088562A1 (en) | 2009-04-02 |
| PT2735568T (pt) | 2017-11-14 |
| CY1120409T1 (el) | 2019-07-10 |
| HK1198388A1 (en) | 2015-04-17 |
| HUE035799T2 (en) | 2018-05-28 |
| WO2008036127A3 (en) | 2008-11-20 |
| AU2007297861A1 (en) | 2008-03-27 |
| CA2651881A1 (en) | 2008-03-27 |
| CY1120486T1 (el) | 2019-07-10 |
| PL2735568T3 (pl) | 2018-02-28 |
| LT2024499T (lt) | 2018-02-26 |
| DK2735568T3 (da) | 2017-11-13 |
| EP2735568A1 (en) | 2014-05-28 |
| DK2024499T3 (da) | 2018-01-29 |
| EP2024499A2 (en) | 2009-02-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI2024499T1 (en) | Analogues of the oligonucleotide, with cationic links between subunits | |
| JP2010505741A5 (enExample) | ||
| HRP20181022T1 (hr) | Analozi oligonukleotida koji ciljaju ljudski lmna | |
| ATE336991T1 (de) | Bis(thio-hydrazid amid) verbindungen zur behandlung von mehrfach resistenten krebs | |
| JP2015501817A5 (enExample) | ||
| McKay et al. | Structure of catabolite gene activator protein at 2.9-A resolution. Incorporation of amino acid sequence and interactions with cyclic AMP. | |
| CA2950960A1 (en) | Polynucleotide constructs having bioreversible and non-bioreversible groups | |
| JP2010500158A5 (enExample) | ||
| AR111481A1 (es) | Sistemas de entrega de liberación sostenida que comprenden enlazadores no rastreables | |
| RU2017101172A (ru) | Антисмысловые нуклеиновые кислоты | |
| JP2015528002A5 (enExample) | ||
| EP3066105A1 (en) | Polynucleotide constructs having disulfide groups | |
| CY1117065T1 (el) | Υβριδικη και διαδοχικη εκφραση νεϊσσεριακα λαμβανομενων πρωτεϊνων | |
| NO20040095L (no) | Taxol-forbedringsbetingelser | |
| PE20161325A1 (es) | L-asparaginasa tratada con peg | |
| BR0211455B1 (pt) | sistema adequado como catalisador, e, processos para a preparaÇço do mesmo, de misturas de mononitrilas c5 mono-olefÍnicas, de uma dinitrila e de adipodinitrila. | |
| IL309001A (en) | Antisense compounds and methods for targeting cug repeats | |
| UY26228A1 (es) | Derivados de eritropoyetina ley 17.164 art. 127 | |
| AR074944A1 (es) | Proceso para la produccion de bivalirudina | |
| HRP20171180T4 (hr) | Pegilirana l-asparaginaza | |
| IL148968A0 (en) | Neutral-cationic lipid for nucleic acid and drug delivery | |
| ATE344231T1 (de) | Polyaspartatharze mit guter härte und flexibilität | |
| JP2009542582A5 (enExample) | ||
| ATE297428T1 (de) | Modifizierte polyamide, zusammensetzungen auf basis dieser polyamide und verfahren zu ihrer herstellung | |
| CY1110047T1 (el) | Μεθοδοι για τον καθαρισμο ραδιοεπισημασμενων προϊοντων χρησιμοποιωντας σαρωτη στερεου-υποστρωματος |